The Medical Letter on Drugs and Therapeutics
Febuxostat (Uloric) for Chronic Treatment of Gout
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Febuxostat (Uloric – Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.

TREATMENT OF GOUT — Most acute attacks of gout can be managed with colchicine, nonsteroidal antiinflammatory drugs (NSAIDs) or corticosteroids.1 However, many patients have elevated uric acid levels that can eventually lead to frequent or refractory attacks, development of tophi (urate deposits that can form large subcutaneous nodules or erode into joints), uric acid renal calculi or other parenchymal involvement. Such patients may benefit from serum urate ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Febuxostat (Uloric) for Chronic Treatment of Gout
Article code: 1312a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian